{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:11:47Z","timestamp":1771038707743,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016086","name":"Key Laboratory in Science and Technology Development Project of Suzhou","doi-asserted-by":"publisher","award":["Szlcyxzx20210"],"award-info":[{"award-number":["Szlcyxzx20210"]}],"id":[{"id":"10.13039\/100016086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40121-025-01224-0","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:39:22Z","timestamp":1757745562000},"page":"2489-2507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of Adverse Drug Reactions of Clofazimine Reported in the FDA Adverse Event Reporting System from 2004 to 2025 Q1"],"prefix":"10.1007","volume":"14","author":[{"given":"Ruoyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunwen","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingwu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4329-9471","authenticated-orcid":false,"given":"Chen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3469-8350","authenticated-orcid":false,"given":"Meiying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"1224_CR1","unstructured":"WHO treatment guidelines for drug-resistant tuberculosis. Update[M]. Geneva: World Health Organization; 2024."},{"key":"1224_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/1791013a0","volume":"179","author":"VC Barry","year":"1957","unstructured":"Barry VC, Belton JG, Conalty ML, et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature. 1957;179:1013\u20135.","journal-title":"Nature"},{"key":"1224_CR3","first-page":"6","volume":"33","author":"SG Browne","year":"1962","unstructured":"Browne SG, Hogerzeil LM. \u201cB 663\u201d in the treatment of leprosy. Preliminary report of a pilot trial. Lepr Rev. 1962;33:6\u201310.","journal-title":"Lepr Rev"},{"key":"1224_CR4","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1128\/AAC.37.12.2584","volume":"37","author":"RT Mehta","year":"1993","unstructured":"Mehta RT, Keyhani A, McQueen TJ, Rosenbaum B, Rolston KV, Tarrand JJ. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis. Antimicrob Agents Chemother. 1993;37:2584\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1224_CR5","first-page":"1083","volume":"151","author":"C Jagannath","year":"1995","unstructured":"Jagannath C, Reddy MV, Kailasam S, O\u2019Sullivan JF, Gangadharam PR. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med. 1995;151:1083\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"1224_CR6","unstructured":"WHO treatment guidelines for drug-resistant tuberculosis. Update[M]. Geneva: World Health Organization; 2020."},{"key":"1224_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00441-22","volume":"66","author":"F Watanabe","year":"2022","unstructured":"Watanabe F, Furuuchi K, Hanada K, et al. Pharmacokinetics and adverse effects of clofazimine in the treatment of pulmonary non-tuberculous mycobacterial infection. Antimicrob Agents Chemother. 2022;66: e0044122.","journal-title":"Antimicrob Agents Chemother"},{"key":"1224_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02687-20","volume":"65","author":"MT Abdelwahab","year":"2021","unstructured":"Abdelwahab MT, Court R, Everitt D, et al. Effect of clofazimine concentration on QT prolongation in patients treated for tuberculosis. Antimicrob Agents Chemother. 2021;65: e0268720.","journal-title":"Antimicrob Agents Chemother"},{"key":"1224_CR9","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1128\/AAC.00260-15","volume":"59","author":"RV Swanson","year":"2015","unstructured":"Swanson RV, Adamson J, Moodley C, et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2015;59:3042\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"1224_CR10","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","volume":"75","author":"MT Abdelwahab","year":"2020","unstructured":"Abdelwahab MT, Wasserman S, Brust JCM, et al. Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother. 2020;75:3269\u201377.","journal-title":"J Antimicrob Chemother"},{"key":"1224_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jmii.2024.08.002","volume":"57","author":"CJ Lin","year":"2024","unstructured":"Lin CJ, Chen JH, Chien ST, et al. Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: findings of adsm in Taiwan. J Microbiol Immunol Infect. 2024;57:791\u2013800.","journal-title":"J Microbiol Immunol Infect"},{"key":"1224_CR12","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1183\/13993003.01207-2016","volume":"48","author":"RS Wallis","year":"2016","unstructured":"Wallis RS. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J. 2016;48:1526\u20137.","journal-title":"Eur Respir J"},{"key":"1224_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","volume":"191","author":"AH Diacon","year":"2015","unstructured":"Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015;191:943\u201353.","journal-title":"Am J Respir Crit Care Med"},{"key":"1224_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/2045125317721662","volume":"7","author":"AD Meid","year":"2017","unstructured":"Meid AD, Bighelli I, Machler S, et al. Combinations of qtc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7:251\u201364.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1224_CR15","first-page":"523","volume":"14","author":"W Zareba","year":"2007","unstructured":"Zareba W. Drug induced QT prolongation. Cardiol J. 2007;14:523\u201333.","journal-title":"Cardiol J"},{"key":"1224_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02445-2016","author":"M Dalcolmo","year":"2017","unstructured":"Dalcolmo M, Gayoso R, Sotgiu G, et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J. 2017. https:\/\/doi.org\/10.1183\/13993003.02445-2016.","journal-title":"Eur Respir J"},{"key":"1224_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26:1033\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1224_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H. Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J Affect Disord. 2024;346:223\u20139.","journal-title":"J Affect Disord"},{"key":"1224_CR19","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","volume":"14","author":"F Zou","year":"2023","unstructured":"Zou F, Zhu C, Lou S, et al. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2023;14:1320458.","journal-title":"Front Pharmacol"},{"key":"1224_CR20","doi-asserted-by":"publisher","first-page":"1161728","DOI":"10.3389\/fphar.2023.1161728","volume":"14","author":"J Wang","year":"2023","unstructured":"Wang J, Zou D, Li Y, Liu P, Guo C. Drug-induced tooth discoloration: an analysis of the US food and drug administration adverse event reporting system. Front Pharmacol. 2023;14:1161728.","journal-title":"Front Pharmacol"},{"key":"1224_CR21","doi-asserted-by":"publisher","first-page":"1170039","DOI":"10.3389\/fphar.2023.1170039","volume":"14","author":"F Wang","year":"2023","unstructured":"Wang F, Zhou B, Sun H, Wu X. Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2023;14:1170039.","journal-title":"Front Pharmacol"},{"key":"1224_CR22","doi-asserted-by":"publisher","first-page":"1382441","DOI":"10.3389\/fphar.2024.1382441","volume":"15","author":"J Wu","year":"2024","unstructured":"Wu J, Pan H, Shen L, Zhao M. Assessing the safety of bedaquiline: insight from adverse event reporting system analysis. Front Pharmacol. 2024;15:1382441.","journal-title":"Front Pharmacol"},{"key":"1224_CR23","doi-asserted-by":"publisher","first-page":"1346169","DOI":"10.3389\/fphar.2024.1346169","volume":"15","author":"IC Celestino","year":"2024","unstructured":"Celestino IC, Antunes DE, Santos DF, Gimenes VL, de Souza FM, Goulart IMB. Adverse reactions induced by MDT\/WHO (rifampicin+clofazimine+dapsone) and ROM (rifampicin+ofloxacin+minocycline) regimens used in the treatment of leprosy: a cohort study in a National Reference Center in Brazil. Front Pharmacol. 2024;15:1346169.","journal-title":"Front Pharmacol"},{"key":"1224_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004143","volume":"4","author":"TJ Hwang","year":"2014","unstructured":"Hwang TJ, Dotsenko S, Jafarov A, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open. 2014;4: e004143.","journal-title":"BMJ Open"},{"key":"1224_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1224_CR26","first-page":"733","volume":"10","author":"S Tang","year":"2019","unstructured":"Tang S, Li L. Chinese expert consensus on multidrug-resistant tuberculosis and Rifampicin-resistant tuberculosis treatment. Chin J Tuberc Respir Dis. 2019;10:733\u2013749.","journal-title":"Chin J Tuberc Respir Dis"},{"key":"1224_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01048-23","volume":"11","author":"R Li","year":"2023","unstructured":"Li R, Ma JB, Yang H, et al. Effects of bedaquiline combined with fluoroquinolone and\/or clofazimine on QT interval in patients with multidrug-resistant tuberculosis: a retrospective study. Microbiol Spectr. 2023;11: e0104823.","journal-title":"Microbiol Spectr"},{"key":"1224_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1515\/jbcpp-2020-0415","volume":"32","author":"D Ardhianto","year":"2021","unstructured":"Ardhianto D, Suharjono, Soedarsono, Fatmawati U. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients. J Basic Clin Physiol Pharmacol. 2021;32:421\u20137.","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"1224_CR29","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/psp4.12722","volume":"10","author":"L Tanneau","year":"2021","unstructured":"Tanneau L, Svensson EM, Rossenu S, Karlsson MO. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis. CPT Pharmacomet Syst Pharmacol. 2021;10:1538\u201349.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1224_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijantimicag.2006.11.011","volume":"29","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents. 2007;29:374\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"1224_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071927","author":"S Park","year":"2022","unstructured":"Park S, Jung J, Kim J, Han SB, Ryoo S. Investigation of clofazimine resistance and genetic mutations in drug-resistant Mycobacterium tuberculosis isolates. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11071927.","journal-title":"J Clin Med"},{"key":"1224_CR32","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1128\/AAC.00753-16","volume":"60","author":"D Almeida","year":"2016","unstructured":"Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60:4590\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1224_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ijid.2020.10.081","volume":"102","author":"Y Liu","year":"2021","unstructured":"Liu Y, Gao J, Du J, et al. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;102:392\u20136.","journal-title":"Int J Infect Dis"},{"key":"1224_CR34","doi-asserted-by":"publisher","first-page":"518","DOI":"10.5414\/CP203784","volume":"58","author":"Q Wu","year":"2020","unstructured":"Wu Q, Ganzert C, Lucke E, Bittmann I, Schreiber J. Fatal course of clofazimine-induced pulmonary crystal deposition in a patient with Melkersson\u2013Rosenthal syndrome. Int J Clin Pharmacol Ther. 2020;58:518\u201322.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1224_CR35","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.4103\/ijmr.IJMR_2263_19","volume":"152","author":"S Divate","year":"2020","unstructured":"Divate S, Sharma S. Pulmonary clofazimine-induced crystal-storing histiocytosis: bronchoalveolar lavage cytological diagnosis. Indian J Med Res. 2020;152:S169.","journal-title":"Indian J Med Res"},{"key":"1224_CR36","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1093\/cid\/ciy624","volume":"67","author":"D Deshpande","year":"2018","unstructured":"Deshpande D, Alffenaar JC, Koser CU, et al. d-Cycloserine pharmacokinetics\/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a faustian deal. Clin Infect Dis. 2018;67:S308\u201316.","journal-title":"Clin Infect Dis"},{"key":"1224_CR37","unstructured":"WHO treatment guidelines for multidrug-and rifampicin-resistant tuberculosis 2018 update Pre-final text[M]. World Health Organization; 2018."},{"key":"1224_CR38","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1186\/s12889-024-20664-w","volume":"24","author":"H Yang","year":"2024","unstructured":"Yang H, Ruan X, Li W, Xiong J, Zheng Y. Global, regional, and national burden of tuberculosis and attributable risk factors for 204 countries and territories, 1990\u20132021: a systematic analysis for the Global burden of diseases 2021 study. BMC Public Health. 2024;24:3111.","journal-title":"BMC Public Health"},{"key":"1224_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","volume":"41","author":"HG Xie","year":"2001","unstructured":"Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815\u201350.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1224_CR40","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","volume":"12","author":"M Guo","year":"2022","unstructured":"Guo M, Shu Y, Chen G, Li J, Li F. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep. 2022;12:20601.","journal-title":"Sci Rep"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01224-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01224-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01224-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:56:45Z","timestamp":1760032605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01224-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01224-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors (Ruoyu Zhang, Yunwen Tao, Ziwei Bao, Jianping Zhang, Lingwu Zeng, Chen Fang, Meiying Wu) declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data used in this study were obtained from the publicly available FDA Adverse Event Reporting System (FAERS) database, which contains de-identified data. Therefore, the data is non-identifiable, and no personal identifying information was included in the dataset. As the data is non-identifiable, there was no need for additional ethical review for individual consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}